Banking on biomarkers for synthetic lethality
How Repare’s biomarker-first approach could differentiate its synthetic lethal cancer programs
Repare thinks its biomarker-first approach could be a key differentiator for its synthetic lethal cancer drug programs. The company is collaborating with test developers ahead of time to recruit patients poised to benefit.
Losing function in two or more genes that have a synthetic lethal relationship triggers cell death,